Skip to main content
Clinical Trials/NCT00254501
NCT00254501
Completed
Phase 3

Empowering Patients to Better Manage Diabetes Through Self-Care

Oregon State University0 sites69 target enrollmentNovember 2005

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Type I or Type II Diabetes (Excludes Gestational Diabetes)
Sponsor
Oregon State University
Enrollment
69
Primary Endpoint
Change in Hemoglobin A-1C From Baseline
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

This study will look at the impact of health insurance benefits on self management of diabetes for people with this condition. Studies have shown that when people with diabetes manage their disease better, they stay healthier. Our goal in this study is to help those with diabetes better manage their disease (self-care). We will compare two types of health insurance benefits in this study. We want to see if one set of benefits improves self-care more than the other one.

Detailed Description

The objective of this particular study is to determine if the addition of regular pharmacist visits to usual care can improve clinical outcomes in patients with diabetes. The central hypothesis is that a program overseen by community pharmacists that empowers patients to self-manage their diabetes will lead to improved clinical and humanistic outcomes and will be cost-effective. Strong preliminary data collected from other sites suggests that patient empowerment programs are effective at reducing hemoglobin A1C after 12 months and in reducing the total cost of care. This hypothesis will be tested by pursuing three specific aims to evaluate the impact of a pharmacist-administered diabetes patient empowerment program on: 1. clinical markers for diabetes and related metabolic disorders; 2. the cost of care and resource utilization; and 3. patient knowledge and perceived ability to manage diabetes. There is an additional specific aim to assess the pharmacists with respect to satisfaction with the training program and the overall project, the activities conducted in patient sessions, and the time taken to complete the visits in this study.

Registry
clinicaltrials.gov
Start Date
November 2005
End Date
June 2011
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dale F Kraemer

Associate Professor

University of Florida

Eligibility Criteria

Inclusion Criteria

  • diabetes (Type I or Type II)
  • enrolled in health plan with participating employer
  • age 18 or older
  • willing and able to provide informed consent

Exclusion Criteria

  • gestational diabetes

Outcomes

Primary Outcomes

Change in Hemoglobin A-1C From Baseline

Time Frame: baseline and 12 months

Compare changes in Hemoglobin A-1C from baseline between the two groups.

Secondary Outcomes

  • Change in Diabetes Knowledge and Empowerment (Patient Self-efficacy) From Baseline to 12 Months(From baseline to 12 months)
  • Changes From Baseline in LDL, HDL, Total Cholesterol, Triglycerides(baseline and 12 months)
  • Changes in Economic Outcomes (Total Cost of Care, Cost of Diabetes Medications, Cost of Diabetes Supplies) From Baseline to 12 Months(baseline to 12 months)

Similar Trials